PMID- 22740475
OWN - NLM
STAT- MEDLINE
DCOM- 20121015
LR  - 20220318
IS  - 1522-2683 (Electronic)
IS  - 0173-0835 (Linking)
VI  - 33
IP  - 12
DP  - 2012 Jul
TI  - Use of MDLC-DIGE and LC-MS/MS to identify serum biomarkers for complete remission 
      in patients with acute myeloid leukemia.
PG  - 1863-72
LID - 10.1002/elps.201200047 [doi]
AB  - The response criteria for complete remission (CR) in acute myeloid leukemia (AML) 
      are currently based on morphology and blood cell counts. However, these criteria 
      are insufficient to establish a diagnosis in cases with poor quality bone marrow 
      (BM) samples demonstrating a loss of cellular morphology. We investigated whether 
      the sera of patients contained biomarkers that indicate disease response status. 
      First, we performed multidimensional liquid chromatography-differential gel 
      electrophoresis (MDLC-DIGE) to generate protein profiles of two pooled, paired 
      serum samples from patients who had achieved CR; one collected at diagnosis 
      (PreCR) and the other collected after chemotherapy (CR). Then, with the biomarker 
      candidates found, ELISA was carried out for individual PreCR and CR samples, and 
      for other verification sets including nonremission (NR) patients and normal 
      samples. We selected two proteins, complement factor H (CFH) and apolipoprotein H 
      (ApoH), with dye (Cy) ratios showing greater than 2.0-fold differences between 
      the pooled samples. ELISA showed that CFH and ApoH are useful for distinguishing 
      between the recovered (CR and normal) and nonrecovered (PreCR, PreNR, and NR) 
      states in AML (p <0.001). We successfully applied a protein profiling technology 
      of MDLC-DIGE and LC-MS/MS to discover two biomarkers for CR which needs further 
      validation for a clinical setting.
CI  - (c) 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Lee, Seung-Won
AU  - Lee SW
AD  - Department of Anatomy, Chonnam National University Medical School, Gwangju, 
      Korea. seunglee@chonnam.ac.kr
FAU - Kim, In Jae
AU  - Kim IJ
FAU - Jeong, Bo Yoon
AU  - Jeong BY
FAU - Choi, Mun-Ho
AU  - Choi MH
FAU - Kim, Jin Young
AU  - Kim JY
FAU - Kwon, Kyung-Hoon
AU  - Kwon KH
FAU - Lee, Jae Won
AU  - Lee JW
FAU - Yu, Ami
AU  - Yu A
FAU - Shin, Myung-Geun
AU  - Shin MG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Electrophoresis
JT  - Electrophoresis
JID - 8204476
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (beta 2-Glycoprotein I)
RN  - 80295-65-4 (Complement Factor H)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/therapeutic use
MH  - Biomarkers, Tumor/*blood
MH  - Chromatography, Liquid/*methods
MH  - Complement Factor H/analysis
MH  - Disease-Free Survival
MH  - Electrophoresis, Gel, Two-Dimensional/*methods
MH  - Female
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*blood/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Tandem Mass Spectrometry/*methods
MH  - beta 2-Glycoprotein I/blood
EDAT- 2012/06/29 06:00
MHDA- 2012/10/16 06:00
CRDT- 2012/06/29 06:00
PHST- 2012/06/29 06:00 [entrez]
PHST- 2012/06/29 06:00 [pubmed]
PHST- 2012/10/16 06:00 [medline]
AID - 10.1002/elps.201200047 [doi]
PST - ppublish
SO  - Electrophoresis. 2012 Jul;33(12):1863-72. doi: 10.1002/elps.201200047.